Eisenhofer G et al: Current progress and future challenges in the biochemical diagnosis and treatment of pheochromocytomas and paragangliomas. Horm Metab Res 2008;40:329.
Ellison KE, Gandhi G: Optimising the use of beta-adrenoceptor antagonists in coronary artery disease. Drugs 2005;65:787.
Fitzgerald JD: Do partial agonist beta-blockers have improved clinical utility? Cardiovasc Drugs Ther 1993;7:303.
Freemantle N et al: Beta blockade after myocardial infarction: Systematic review and meta regression analysis. BMJ 1999;318:1730.
Hogeling M, Adams S, Wargon O: A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics 2011;128:e259.
Jacobs DS: Open-angle glaucoma: Treatment. UpToDate.com 2013, topic 15695.
Kamp O et al: Nebivolol: Haemodynamic effects and clinical significance of combined β-blockade and nitric oxide release. Drugs 2010;70:41.
Kaplan SA et al: Combination therapy using oral β-blockers and intracavernosal injection in men with erectile dysfunction. Urology 1998;52:739.
Kyprianou N: Doxazosin and terazosin suppress prostate growth by inducing apoptosis: Clinical significance. J Urol 2003;169:1520.
Lanfear DE et al: β2-Adrenergic receptor genotype and survival among patients receiving β-blocker therapy after an acute coronary syndrome. JAMA 2005;294:1526.
Lepor H et al: The efficacy of terazosin, finasteride, or both in benign prostate hyperplasia. N Engl J Med 1996;335:533.
Maggio PM, Taheri PA: Perioperative issues: Myocardial ischemia and protection– beta-blockade. Surg Clin North Am 2005;85:1091.
McVary KT: Alfuzosin for symptomatic benign prostatic hyperplasia: Long-term experience. J Urol 2006;175:35.
Nickel JC, Sander S, Moon TD: A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract 2008;62:1547.
Nickerson M: The pharmacology of adrenergic blockade. Pharmacol Rev 1949;1:27.
Okamoto LE et al: Nebivolol, but not metoprolol lowers blood pressure in nitric oxide-sensitive human hypertension. Hypertension 2014;64:1241.
Perez DM: Structure-function of alpha1-adrenergic receptors. Biochem Pharmacol 2007;73:1051.
Pojoga L et al: Beta-2 adrenergic receptor diplotype defines a subset of salt-sensitive hypertension. Hypertension 2006;48:892.
Raj SR et al: Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: Less is more. Circulation 2009;120:725.
Robertson D et al: Primer on the Autonomic Nervous System, 3rd ed. Cambridge, MA: Academic Press, 2012.